Group items tagged

If you are a music lover, then you are definitely at the correct place. Nowadays, music had become a passion, a basic need of every human. If you too are a sucker for music and are looking for speakers that wouldn't burn a hole in your pocket then here are 10 best bluetooth speakers under 5000 rupees that you can get in India:

Down syndrome is also known as DS or DNS. This is a genetic disorder. Our human body is made of millions of cells.

Health is an important asset to human beings. Patients, physicians, medical billing companies, insurance companies, clearinghouses, all are connected in one way or another to offer quality services. Physicians are then reimbursed for their services and that's how the process flows.

Health is an important asset to human beings. Patients, physicians, medical billing companies, insurance companies, clearinghouses, all are connected in one way or another to offer quality services. Physicians are then reimbursed for their services and that's how the process flows.

The liver is truly the engine of the human body. It plays multiple roles, which include aiding the digestive system, metabolism and manufacturing the compounds that are essential to keep the body healthy. In fact, the liver is responsible for converting clear plasma (Rasa Dhatu) present inside the body into blood (Rakta Dhatu).

HBO's latest offering 'Chernobyl'has grabbed a lot of attention in the last few days since it was released. This mini-series, co-starring Jared Harris, Emily Watson and StellanSkarsgard, is a very grave picturization of one of the worst human disasters in modern history. Written by Craig Mazin (of "The Hangover" Parts II and III fame) and directed by Johan Renck, this five-episode series brings back to life the tragic event of 1986 in erstwhile USSR and does not shy away from showing the horrors committed during that time. It gives the audience a glimpse of the events before, during and after the nuclear explosion, ill effects of which can be seen in Europe till date.

Ugghhh!! Summers are not just here but dreadfully taking a toll on all of us. We humans can at least choose to decide on our recreations to drive away our summer blues. But, what about your darling pet dogs? They too might be longing for some entertaining activities but can't express. I am sure you all must be deeply in love with your fur pals and already be doing anything and everything to keep them happy and healthy. But, just imagine those glaring eyes in your locality when you take your dog for a stroll. I am sure you must have come across such people because of whom you don't feel comfortable taking your dogs to public places. Also, if you do take your dog out, the poor thing must wear a leash. Can you imagine putting your pet in the community pool? Your pet might be clean and disciplined. But other people are not so considerate.

In such overwhelming times, when healthcare workers face the challenge of a growing number of COVID-19 patients on one side, they are required to follow the rules of HIPAA remote care on the other. They are under obligation to meet HIPAA security and privacy requirements no matter how big or small their practice is.

Working from home is a new reality. The novel coronavirus has left us at home while it continues to affect the human race. It doesn't differentiate between humans based on their race, wealth, color, sex, or religion; moreover, it treats the young and grownups alike.

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation. It doesn't stop there, but HIPAA penalties won't apply to covered healthcare providers for practicing telehealth medicine using third-party applications such as Skype or Facebook Messenger

The Office for Civil Rights (OCR) at the U.S. Department of Health and Human Services has announced relaxation in HIPAA rules for covered entities and business associates who participate in good faith in the COVID-19 testing site operation.

The Department of Health and Social Care (DHSC) has commenced a consultation on allowing pharmacists to dispense prescription medicines in original packaging. The consultation, closing on December 13, 2021, proposes changes to the Human Medicines Regulations (HMRs). It would allow pharmacists to dispense more or less than the 10 per cent of the prescribed quantity in original packs, except where this would affect the patient's clinical treatment. The change would not apply to controlled drugs. The second proposed change is to supply sodium valproate in original packaging regardless of the conditions set around Original Pack Dispensing (OPD). Currently, contractors have to supply the exact quantity prescribed, unless certain exceptions apply.

The Royal Pharmaceutical Society is set to cease all its remaining financial investments in fossil fuels latest by the end of 2022. The decision taken today (November 17) at the RPS Assemble, is part of the organisation's "continued drive to become an environmentally responsible organisation." Calling it a significant move, RPS president Claire Anderson said: "RPS will divest from fossil fuels as soon as possible. "RPS will instruct its investment managers immediately to ensure that we will be completely disinvested by the end of 2022 and hopefully sooner." Environment and human wellbeing have always been a core consideration of RPS investment, however it was not enough to offset the negative impacts of climate change, the organisation said.

Bas Vorsteveld, who was made vice president and general manager for Great Britain & Ireland (GBI) in November last year, is joined by Monica Michalopoulou as GBI marketing director and Onyeka Anugwom as GBI commercial excellence director GSK Consumer Healthcare. He took over from Jonathan Workman, who held the position from 2018, and has now moved into the role of Business Unit general manager for Northern Europe. Vorsteveld, who has 15 years' industry experience, played at major part in the merger of Novartis and GSK consumer healthcare businesses. Most recently, he held the role of VP & head of commercial excellence EMEA LATAM at GSK Consumer Healthcare, where he spearheaded international sustainability initiatives. Commenting on his new role, Vorsteveld said: "I am incredibly honoured to have been a part of GSK Consumer Healthcare's journey to date and it is our collective ambition to deliver better everyday health with humanity for our customers, with a laser focus on 'self-care'. "The recent pandemic has shown us that healthcare matters more now than ever before for our consumers. We want to redefine the role that self-care plays in people's lives, because it can bring long-term benefits for individuals and society, and is a key component of a sustainable healthcare system.

A pioneering study by UCL researchers has found that just three minutes of exposure to deep red light once a week, when delivered in the morning, can significantly improve declining eyesight. Published in the journal Scientific Reports, the study builds on the team's previous work, which showed daily three-minute exposure to longwave deep red light 'switched on' energy-producing mitochondria cells in the human retina, helping boost naturally declining vision. For this latest study, scientists wanted to establish what effect a single three-minute exposure would have, while also using much lower energy levels than their previous studies. Furthermore, building on separate UCL research in flies that found mitochondria display 'shifting workloads' depending on the time of day, the team compared morning exposure to afternoon exposure.

Both head of customer operations Dan Britton and chief executive Michael Brodie at the NHS Business Services Authority (NHSBSA) have won the Inspiring Leaders Award, which recognises leaders for their humanity and courage. The coveted award, organised by Inspiring Workplaces, recognised their contribution during the pandemic. Under Brodie's leadership, who joined the organisation as chief executive in September 2019, NHSBSA started over 50 new services to support the wider NHS. He also led Public Health England (PHE) through its transition to the new UK Health Security Agency. Miranda Sykes, head of communications and marketing at NHSBSA said: "Michael is an inspirational leader for many reasons. He cares immensely and he's spent the pandemic thinking about others and using his influence to support the NHS over the last 18 months or so." His decision to take up an additional CEO role while transforming the PHE during the pandemic shows "Michael's style of leadership is authentic, inclusive and empathetic. He is passionate about the NHS and doing everything he can to support it."

Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four drug candidates intended for use as licensed pain medications. The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome. The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to confirm its value as a potential drug. Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.

The regulatory amendments proposed will enable pharmacists to dispense medicines in their original packaging for private prescriptions starting this Autumn, according to the Department of Health and Social Care. In the recently published draft OPD regulations, the DHSC has indicated that the alterations, permitting pharmacists to vary the dispensed quantity by up to 10 per cent to avoid splitting medicine packs, will be implemented for private prescriptions 'immediately upon the enforcement of the Human Medicines Amendment Regulations in the autumn,' as highlighted in a briefing by Community Pharmacy England. CPE stated that the regulations related to NHS prescriptions will come into effect when the pharmaceutical terms of service regulations expressly apply the OPD amendments. Moreover, new directive mandating the dispensing of sodium valproate products solely in their original packaging (except when an assessment of risk necessitates an alternative approach) will align with the rollout of the private prescription regulations during the autumn. CPE further noted that these regulations are currently in draft, indicating that they are not currently in effect and may undergo revisions prior to their implementation.

The Department of Health and Social Care aims to amend the Human Medicines Regulations 2012, thereby enabling pharmacy technicians to provide and administer specific medicines through a patient group direction. In line with this initiative, the Department introduced a six-week consultation to assess whether registered pharmacy technicians should be authorised to dispense medicines using a PGD. The proposals, backed by all four Home Nations, apply exclusively to registered pharmacy technicians. Meanwhile, this coverage will extend to include pharmacy technicians in Northern Ireland upon their achievement of registered professional status. "The proposed statutory instrument, presently applicable in England, Scotland, and Wales would offer 'clear benefits,' especially in areas such as vaccination and the provision of oral contraception and EHC," the DHSC said. According to the Department, facilitating registered pharmacy technicians to execute PGDs might amplify their workload, yet it could simultaneously enhance overall efficiency and cost-effectiveness for pharmacy teams by optimising the utilisation of skill diversity.

A couple in Maidenhead, Berkshire has been handed suspended sentence for illegal possession and supply of £1.6m of unlicensed medicines. Following investigations initiated by the MHRA, Karina Filimonova and Andrejs Stolarovs were caught with the unlicensed medicines which included prescription-only medications. Southwark Crown Court sentenced each "to eight months imprisonment suspended for 18 months and 150 hours unpaid work" for possessing and intending to supply medicinal products contrary to the Human Medicines Regulations 2012. "This was a sophisticated operation illegally bringing unlicensed medicines into the UK from Singapore and India, and then distributing them across the country and abroad," said Andy Morling, MHRA Deputy Director of Criminal Enforcement. "Criminals trading in medicines illegally like this are not only breaking the law, but they also have no regard for your safety. These are powerful medicines that can lead to serious adverse health consequences if taken without appropriate medical supervision." In 2020, the Royal Mail Group (RMG) informed the MHRA about parcels containing unlicensed medicines discovered during their investigation into suspicious parcel activity. Following this, the MHRA's Criminal Enforcement Unit, in cooperation with local police, launched an investigation and apprehended the couple at their residence in Kidwells Close, Maidenhead.

The liver is a vital organ in the human body that performs several crucial functions such as filtering toxins from the blood, producing bile, and storing energy.

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.